Objective To compare the efficacy and safety of theophylline or aminophylline for prevention of acute kidney injury (AKI) in neonates and children. Design Systematic review and meta-analysis with application of Grading of Recommendations, Assessment, Development and Evaluation system. Data sources PubMed/MEDLINE, Embase, Google Scholar and Cochrane renal group were searched from 1970 to May 2018. Eligibility criteria Randomised clinical trials and quasi-randomised trials comparing the efficacy and safety of prophylactic theophylline or aminophylline for prevention of AKI in neonates and children were included. The primary outcomes were: incidence of AKI, serum creatinine levels and all-cause mortality. results A total of nine trials were included in the qualitative synthesis. Six trials including 436 term neonates with birth asphyxia who received a single dose of theophylline were finally included in the meta-analysis. The pooled estimate showed 60% reduction in the incidence of AKI in neonates with severe birth asphyxia (RR: 0.40; 95% CI 0.3 to 0.54; heterogeneity: I 2 =0%) (moderate quality evidence), decrease in serum creatinine over days 2-5 (very low to low quality evidence) without significant difference in all-cause mortality (RR: 0.88; 95% CI 0.52 to 1.50; heterogeneity: I 2 =0%) (very lowquality evidence). A significant difference in the negative fluid balance, increase in GFR and decrease in urinary β2 microglobulin was seen in favour of theophylline. Conclusion and relevance A single dose of prophylactic theophylline helps in prevention of AKI/ severe renal dysfunction in term neonates with severe birth asphyxia (moderate quality evidence) without increasing the risk of complications and without affecting all-cause mortality (very low-quality evidence). Trial registration number CRD 42017073600.
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InTrODuCTIOn
Acute kidney injury (AKI) is defined as a rapid loss in kidney function (hours to days), resulting in derangements in fluid balance, electrolytes and waste products. 1 AKI may result from impaired renal perfusion, exposure to nephrotoxic drugs, sepsis or ischaemia during surgery, such as cardiopulmonary bypass. 2 In a recent prospective national cohort study using electronic alert system, the incidence of hospital and community acquired AKI in children was found to be 40.1% and 29.4%, respectively. 3 The reported incidence of neonatal AKI ranges from 8.4% to 34.5% [3] [4] [5] and is associated with increased mortality, longer duration of hospital stay and an increased cost. 6 7 A systematic review of large cohort studies conducted between 2004 to 2012 showed a pooled incidence of AKI in 33.7% children and a pooled mortality rate of 13.8%. 8 Despite increased mortality, there are few modalities for prevention and treatment of AKI.
Some of the previous studies and randomised controlled trials (RCTs) have shown renoprotective role of theophylline and aminophylline in term [9] [10] [11] [12] [13] and preterm neonates with severe birth asphyxia, 14 children undergoing cardiac surgery 15 16 and in preterm neonates with respiratory distress syndrome. 17 A previous systematic review had shown improved outcome with use of a single dose of theophylline. 18 Since then, two RCTs have been published. 9 19 The previous review focused mainly on neonates with severe birth asphyxia; the description of outcome data was limited, and treatment emergent complications were excluded from the final meta-analysis. Thus, we conducted this updated systematic review including RCTs and quasirandomised trials to explore the present evidence for the use of adenosine antagonists for prevention of AKI. We used the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) 20 approach to rate quality of evidence for primary outcomes and present our results with GRADE summary tables, which was also lacking in the previous systematic review.
What is already known on this topic?
► Acute kidney injury (AKI) is associated with increased mortality, longer duration of hospital stay and an increased cost. ► Care for neonates and children with AKI remains supportive.
What this study adds?
► A single dose of adenosine antagonists reduces the incidence of AKI in term neonates with severe birth asphyxia by 60% without increasing the risk of complications (moderate quality evidence). ► Prophylactic theophylline given to neonates with severe birth asphyxia also decreases serum creatinine, maintains negative fluid balance and increases glomerular filtration rate. 
Original article ObjECTIvE
To describe the efficacy and safety of theophylline or aminophylline compared with standard therapy or placebo for prevention of AKI in neonates and children.
METhOD
We included RCTs and quasi-RCTs (trials where allocation is not truly random, eg, by alternation, use of alternate medical record numbers, date of birth or other methods with a potential for selection bias).
Types of participants
Neonates and children (0-18 years) who received theophylline or aminophylline for prevention of AKI and compared with standard therapy or placebo were eligible. Exclusion criterion were: children with pre-existing renal disease, history of tachyarrhythmias, seizures, cardiac transplant recipients, small for gestational age, neonates requiring mechanical ventilation or history of drug intake by mother causing fetal and neonatal depression, children/infants requiring renal replacement therapy, deranged liver enzymes (>3 times normal) and coagulopathy. The definition of AKI was taken as used in the individual study (table 1) .
search methods for identification of studies
Cochrane Central Register of Controlled Trials, PubMed/ MEDLINE, Embase, Google Scholar and Cochrane renal group were searched from 1970 to May 2018. The following search strategy was applied: ((((((adenosine receptor antagonist) OR adenosine antagonist) OR theophylline) OR aminophylline) OR caffeine)) AND ((((((((acute kidney injury) OR acute renal failure) OR acute Kidney Failure) OR renal failure) OR acute renal insufficiency) OR renal insufficiency) OR renal dysfunction) OR acute renal injury)) AND (((((((Neonates) OR Newborn Infant) OR infant) OR preschool) OR toddler) OR paediatric) OR children). The paediatric age group includes patients up to 18 years.
Types of outcome measures
The primary and secondary outcomes were defined before the collection of data. The outcome measures were collected day wise up to 5 or 7 days as specified in individual trials. 
Data extraction (selection and coding)
Data were collected using a pilot tested data extraction form. Two authors (GCB and PG) independently extracted data including author, type of population, exposure/intervention (theophylline or aminophylline vs standard therapy or placebo), results (outcome measures, effect and significance) and sources of funding/support. Any disagreement in the extracted data was resolved by discussion with the third author (MB).
risk of bias (quality) assessment
Two review authors (GCB and RRD) independently assessed the quality of the included trials by using Cochrane methodological quality assessment forms. 22 
strategy for data synthesis
The data were pooled and expressed as mean difference (MD) with 95% CI for continuous data and risk ratio (RR) with 95% CI for categorical data. A p value <0.05 was considered significant. I 2 statistics was used for assessment of heterogeneity. In case of high-level heterogeneity (>50%), we tried to explore the cause. A fixed effect model was initially conducted and if significant statistical heterogeneity existed between trials (I 2 >50%), potential sources of heterogeneity were considered and where appropriate a random effects model was used. RevMan (Review Manager) V.5.2 was used for all the analyses.
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Publication bias
For publication bias, we used inverted funnel plot as suggested by Egger et al.
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Grade of evidence
For assessment of the quality of evidence we used GRADE Profiler software (V.3.2). 25 GRADE assessment of evidence quality reflects confidence in the estimates of benefits or harms. GRADE is implemented with four levels of evidence quality, namely, high, moderate, low and very low. Rating is made for each outcome based on study design, risk of bias, imprecision, indirectness and magnitude of effect. 26 'Summary of findings (SOF)' tables were constructed by using GRADE profiler, and only primary outcomes were included in SOF tables.
sensitivity analysis
We evaluated the impact of methodological quality by removing the trials at high or unclear risk of bias for random sequence generation and allocation concealment.
rEsulTs
A total of 88 citations were retrieved by using the search strategy; after duplicate removal, 84 articles were available for screening of which 73 were excluded (title and/or abstract not relevant). The full texts of the remaining 11 articles were assessed for eligibility (figure 1). After further exclusion of two articles (one has evaluated the role of aminophylline in patients with chronic kidney disease (CKD), one has experimental drug in both the arms), nine trials were finally included in the qualitative synthesis (table 1) . Six trials, 9-13 19 with 436 participants, evaluated the effect of prophylactic theophylline for the prevention of severe renal dysfunction in term neonates with severe birth asphyxia. One trial 17 evaluated the role of theophylline in preterm neonates <32 weeks' gestation with respiratory distress syndrome, two trials evaluated the role of aminophylline-one in preterm neonates with birth asphyxia 14 and another in infants and children undergoing cardiac surgery with cardiopulmonary bypass. 15 Severe renal dysfunction was defined by following criteria: serum creatinine >1.5 mg/dL for at least two consecutive days or rising levels of serum creatinine (0.3 mg/day) per day.
Blinding of outcome assessor not clear. Theophylline levels were measured.
Bakr 12
Single-centre NICU, Egypt Numbers (n=40): theophylline group (n=20), placebo group (n=20).
Age: term and post-term newborns.
Inclusion criterion: newborns with severe birth asphyxia defined by: 5 min Apgar score of 6 or lower, base deficit >15 mEq/L in cord or admission blood gas, requirement of vigorous resuscitation. Exclusion criterion: preterm and small for gestational age and neonates with congenital abnormality and dysmorphism.
Theophylline group received single dose of 5 mg/kg theophylline intravenously over 5 min.
Placebo group received 2 mL of 10% dextrose. Severe renal dysfunction was defined as: serum creatinine of >1.5 mg/dL for two consecutive days.
Random sequence generation, allocation concealment and binding of outcome assessor not clear. Theophylline levels not done.
Bhat et al 10 Single centre (NICU), India. Numbers (n=70): theophylline group (n=40); placebo group (n=30).
Age: term and post-term neonates.
Inclusion criterion: neonates with severe perinatal asphyxia defined by: history of fetal distress, need for immediate ventilation and a 5 min Apgar score of ≤6, base deficit ≥15 mEq/L in cord blood or admission or cord blood PH <7. Exclusion criterion: drugs used by mother that can affect renal haemodynamics and renal function, any condition unrelated to asphyxia, cardiovascular disease unrelated to asphyxia, congenital malformation of the kidneys or urogenital tract, polycythaemia, microcephaly and chromosomal disorders or severe intrauterine growth disorders.
Theophylline group received 8 mg/kg intravenous theophylline over 5 min. Placebo group received equal amount of 5% dextrose in water. 15 17 and the rest seven trials have unclear risk of bias in one more domains (random sequence generation, allocation concealment, blinding and selective reporting) without any domain for high risk of bias (online supplementary figure 1 ). The risk of bias for random sequence generation was unclear in three trials. 10 12 14 The risk of bias for allocation concealment was unclear in five trials. 10-12 14 19 The risk of performance bias was unclear in four trials. 9 11 14 19 The risk of detection bias was unclear, attrition and other bias was low, in all the nine trials. Reporting bias was low in all except one trial.
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Theophylline versus placebo for prevention of AKI in term neonates with severe birth asphyxia
Theophylline was given in a single doses of 5mg/kg in four trials 9 11 12 19 and 8mg/kg in two trials. 10 13 Primary outcome measures 1. Incidence of AKI: six trials, 9-13 19 with 436 participants reported this outcome. The pooled estimate showed 60% reduction in the incidence of AKI in the neonates with severe birth asphyxia receiving single dose of prophylactic theophylline compared with placebo (RR: 0.35; 95% CI 0.25 to 0.49; I²=0%) (figure 2).
Creatinine levels during initial 5 days: this outcome was
reported by six trials. 9-13 19 A high degree of unexplained heterogeneity was noted for this outcome. There was no significant difference between the creatinine levels on day 1 (mean difference (MD): −0.24; 95% CI −0.72 to 0.24; I 2 =98%). Over the next 2-5 days, there was a significant decrease in serum creatinine levels in neonates who received theophylline (day 5 level: [MD: −0.38; 95% CI −0.56 to -0.21; I 2 =85%]) (figure 3). 3. All-cause mortality: five trials [9] [10] [11] [12] [13] with 356 participants reported 47 deaths. The pooled estimated showed 12% reduction of mortality in neonates who received prophylactic theophylline. However, the difference between the two groups was not significant (RR: 0.88; 95% CI 0.52 to 1.50; I 2 =0%) (figure 4). figure 3 ). 3. Urinary β2 globulin levels during the initial 5 days: three trials reported this outcome. 10 12 13 The pooled results showed significantly lower mean urine β2 microglobulin (B 2 M) concentrations, used as a marker of tubular injury 27 Original article a. Requirement of ventilatory support: two trials with 195 participants reported this outcome. There was no significant difference between treatment and control group (RR: 0.75; 95% CI 0.43 to 1.31; I 2 =44%). b. Requirement of inotropic support: four trials 9 10 12 13 with 320 participants reported this outcome without significant difference between groups (RR: 0.92; 95% CI 0.68 to 1.25; I 2 =0%). c. Seizures: four trials 9 11-13 with 286 participants reported this outcome without significant difference between groups (RR: 0.79; 95% CI 0.56 to 1.12; I 2 =0%).
Theophylline for preterm infants with respiratory distress syndrome
We identified a single, double-blind randomised, placebo controlled trial examining the effect of intravenous theophylline in preterm neonates with respiratory distress syndrome at a dose of 1 mg/kg for 3 days. 17 The incidence of oliguria was decreased in preterm neonates receiving theophylline on day 1 (RR: 0.14; 95% CI 0.02 to 1.05), but the difference did not extend to the subsequent 10 days. Serum creatinine levels on day 24 were insignificantly lower in neonates who received theophylline compared with placebo (MD: −22.50; 95% CI −39.25 to 5.75). Similarly, creatinine levels on days 3 to10 did not differ significantly between groups. All-cause mortality and other secondary outcomes were not reported.
Aminophylline for preterm neonates with perinatal asphyxia
One trial examined the effect of a single dose of aminophylline on renal function and markers of AKI (N-acetyl-glucosaminidase and B 2 M) on days 1, 4 and 7 of life.
14 Aminophylline (5 mg/kg) was given to preterm neonates with perinatal asphyxia(n=11) within the first hour after birth and compared with placebo (n=11). Aminophylline-treated infants demonstrated significantly higher eGFR on day 4 compared with placebo with no difference in NAG and B 2 M levels and increased urine output from day 1. Incidence of AKI, all-cause mortality and other secondary outcomes were not reported.
Aminophylline for children less than 18 years with congenital heart defects undergoing cardiac surgery
One trial reported use of aminophylline in postoperative children after congenital heart surgery with cardiopulmonary bypass. 15 This was a double-blind randomised placebo controlled trial where the experimental group (n=72) received intravenous aminophylline (5 mg/kg loading dose followed by 1.8 mg/kg every 6 hours for 72 hours) (n=72) and the control group isotonic saline (placebo) matched by volume and appearance. Study drug was discontinued in 24% of the patients in the experimental arm and 15% of subjects in the placebo group. There was no difference in the incidence and stage of serum creatinine-based AKI or urine output between the two groups. A subgroup analysis (<3 months old) showed no difference between the outcomes, but this analysis was insufficiently powered. Adverse event rates were similar in both groups.
Treatment emergent adverse events
These were reported in seven 9-13 15 17 of nine trials. They were mainly related to the disease process and occurred with similar frequency in either group. Table 2 shows treatment emergent adverse events and whether the treatment emergent adverse events were defined as one of the outcomes.
sensitivity analysis
As all the six included trials of theophylline versus placebo for prevention of AKI in neonates with severe birth asphyxia were having one or more domains of unclear risk of bias, we could not perform sensitive analysis.
Publication bias and small effect
Due to the paucity of published studies (<10), a funnel plot was not constructed.
Grade of evidence
The grade evidence generated for the comparison of theophylline versus placebo for prevention of AKI in neonates with birth asphyxia was as follows: 'moderate' quality for incidence of AKI/severe renal dysfunction, and 'very low' to 'low' quality for serum creatinine levels on days 1-5 and all-cause mortality (table 3) . This was because of serious study limitations (unclear risk of bias in one or more domains of random sequence generation, allocation concealment, blinding and selective reporting), a very high and statistically significant heterogeneity and the 95% CI includes null effect and/or appreciable benefit or harm. Original article DIsCussIOn summary of evidence An extensive literature search in the present systematic review revealed nine trials to be eligible for inclusion. Of these, the data from six trials enrolling 436 neonates who were given prophylactic theophylline as compared with placebo were meta-analysed. The findings of the present systematic review indicate that single dose of prophylactic theophylline given to term neonates with severe birth asphyxia decreases the incidence of AKI/severe renal dysfunction by 60% (moderate quality evidence) compared with placebo and decreases serum creatinine levels from days 2 to 5 (very low to low-quality evidence) without significant difference in mortality between the two groups (very low quality evidence). For the secondary outcomes, there was a significant difference in the negative fluid balance in favour of theophylline, increase in glomerular filtration rate (GFR), decrease in urinary B 2 M and without significant difference in complication rate between the two groups. Thus, the modest transient increase in diuresis and negative fluid balance associated with theophylline may be beneficial as they can possibly act as surrogate markers of hard clinical outcomes such as mortality, ICU and hospital length of stay, and long-term chronic kidney disease, which needs to be determined in future studies. 28 AKI has been reported to range from 30% to 70% in neonates with birth asphyxia. 29 30 AKI in the perinatal asphyxiated neonates increases the mortality to as high as 60%, especially in neonates with low Apgar score at 5 min, oliguria and fluid overload of more than 20%. 31 32 A recent trial 9 that recruited 159 severely asphyxiated term neonates showed that the neonates receiving single prophylactic dose of theophylline had a lower creatinine levels, had higher creatinine clearance and significantly decreased risk of AKI/severe dysfunction. The authors also found a lower mortality rate in the neonates who received prophylactic theophylline, though the difference was not statistically significant. A secondary analysis from the Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates (AWAKEN) study found that caffeine administration in preterm neonates was associated with reduced incidence and severity of AKI. 33 Experimental studies in animals have shown that renal adenosine act as a vasoconstrictive metabolite in the kidney after hypoxia causing fall in GFR and filtration factor. 34 Thus, non-specific adenosine receptor antagonists such as theophylline inhibits vasoconstriction produced by adenosine. Another experimental study using 8-cyclopentyl-1,3-dipropylxanthine, a specific antagonist of the A1 adenosine receptors found it to be less effective than theophylline in preventing hypoxia-induced renal failure, thus implicating that the later agent may act on the other targets than adenosine A1 receptors. 35 Theophylline has wide variation in metabolism and a narrow therapeutic window, and hence, it is essential to measure theophylline levels to avoid toxicity. 36 Only three 13 15 17 of nine included studies in the qualitative synthesis measured the theophylline levels. The pooled estimate showed no significant difference in the complication rates between the two groups in the present systematic review.
strengths and limitations
Strengths: (1) it is an updated systematic review with broader search question and inclusion of two recent trials; and (2) rigorous use of GRADE approach to rate quality of evidence. Limitations: (1) single trial studying the effect of adenosine antagonists for prevention of AKI in infants undergoing cardiac surgery, preterm neonates with birth asphyxia and respiratory distress syndrome; (2) no long-term follow-up beyond neonatal period in most of the studies; and (3) role of theophylline or aminophylline not evaluated in neonates receiving therapeutic hypothermia, which has now emerged as standard of care for perinatal asphyxia.
COnClusIOns
This updated meta-analysis showed a benefit (decreased incidence of AKI/severe renal dysfunction) of theophylline in term neonates with severe birth asphyxia (moderate quality evidence) without significant adverse effects or effect on the mortality (very low-quality evidence). However, the long-term effect of these outcomes as well as potential toxicity if any needs to be investigated in further trials and in the setting of therapeutic hypothermia for birth asphyxia. More good quality trials reporting all the outcomes are needed for the beneficial effect of theophylline in preterm neonates with birth asphyxia and in infants undergoing cardiopulmonary bypass surgery.
